{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.96","upperLimit":"33.99","value":"26.2"},{"groupId":"OG001","lowerLimit":"52.28","upperLimit":"69.27","value":"61.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"description":"To evaluate the PFS rate at 1 year in each treatment arm by investigator","dispersionType":"95% Confidence Interval","groups":[{"description":"Gemcitabine 1000 mg/m² IV are given on Days 1 \\& 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，placebo will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and placebo for up to 2 years","id":"OG000","title":"Placebo Combine With Chemotherapy"},{"description":"Gemcitabine 1000 mg/m² IV are given on Days 1 \\& 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，JS001 will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and JS001 for up to2years","id":"OG001","title":"TORIPALIMAB INJECTION(JS001 )Combine With Chemotherapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to approximately 1years","title":"Investigator-assessed PFS Rate at 1 Year","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}